Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Luying Wang, Weili Gu, Xiao Zhang, Shihui Fu, Donger Zhang, Xin Guan, Hongchao Li & Aixia Ma. (2022) How the cost-effectiveness results change in the China health policy environment: an economic evaluation of glycopyrrolate/formoterol for the treatment of COPD. Journal of Medical Economics 25:1, pages 356-366.
Read now
Read now
Edward Kerwin, Paul Dorinsky, Mehul Patel, Kimberly Rossman, Colin Reisner, Andrea Maes, Patrick Darken, Dianne Griffis & Harald Fjällbrant. (2022) A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment. Journal of Asthma 59:7, pages 1420-1432.
Read now
Read now
Omar S Usmani, Nicolas Roche, Martin Jenkins, Neda Stjepanovic, Peter Mack & Wilfried De Backer. (2021) Consistent Pulmonary Drug Delivery with Whole Lung Deposition Using the Aerosphere Inhaler: A Review of the Evidence. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 113-124.
Read now
Read now
Pierre-Edouard Grillet, Cosette Le Souder, Juliette Rohou, Olivier Cazorla, Jérémy Charriot & Arnaud Bourdin. (2021) Glycopyrrolate and formoterol fumarate for the treatment of COPD. Expert Review of Respiratory Medicine 15:1, pages 13-25.
Read now
Read now
Donald P Tashkin. (2020) Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 3105-3122.
Read now
Read now
Bo Ding, Lee Kallenbach, Lukas Slipski, Alan Wilk, Dan O’Brien & Deniz Guranlioglu. (2020) Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 775-786.
Read now
Read now
Fernando J Martinez, Klaus F Rabe, Brian J Lipworth, Samir Arora, Martin Jenkins, Ubaldo J Martin & Colin Reisner. (2020) Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 99-106.
Read now
Read now
Rongchang Chen, Nanshan Zhong, Hao-Yan Wang, Li Zhao, Xiaodong Mei, Zhiqiang Qin, Juan Huang, Pryseley N Assam, Andrea Maes, Shahid Siddiqui, Ubaldo J Martin & Colin Reisner. (2020) Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 43-56.
Read now
Read now
Articles from other publishers (23)
Mingjin Yang, Yishi Li, Youfan Jiang, Shuliang Guo, Jian-Qing He & Don D. Sin. (2023) Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. European Respiratory Journal 61:2, pages 2200302.
Crossref
Crossref
Afisi S. Ismaila, Katrin Haeussler, Alexandrosz Czira, Vanita Tongbram, Mia Malmenäs, Jatin Agarwal, Maria Nassim, Marija Živković-Gojović, Yunrong Shen, Xinzhe Dong, Maria Duarte, Chris Compton, Claus F. Vogelmeier & David M. G. Halpin. (2022) Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis. Advances in Therapy 39:11, pages 4961-5010.
Crossref
Crossref
E. A. Orlova, I. P. Dorfman, M. A. Orlov & M. A. Abdullaev. (2022) The double bronchodilation era: new capabilities in a new drug delivery device. Meditsinskiy sovet = Medical Council:4, pages 128-137.
Crossref
Crossref
Sundeep Salvi, Anand Kumar, Sumit Agrawal, Amritlal Leuva, VineetKumar Shukla, ShrikantVishnu Deshpande, Santhalingam Balamurugan, Ajit Singh, Sharad Tikkiwal, SandeepK Gupta, BhanuPratap Singh, Meena Lopez, Sandesh Sawant, Abhijit Vaidya & Jaideep Gogtay. (2022) Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study. Lung India 39:5, pages 408.
Crossref
Crossref
Dave Singh, John R. Hurst, Fernando J. Martinez, Klaus F. Rabe, Mona Bafadhel, Martin Jenkins, Domingo Salazar, Paul Dorinsky & Patrick Darken. (2022) Predictive modeling of COPD exacerbation rates using baseline risk factors. Therapeutic Advances in Respiratory Disease 16, pages 175346662211073.
Crossref
Crossref
Yiwen Gong, Yinghua Lv, Hongxia Liu, Qingshan Zheng & Lujin Li. (2022) Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD. Therapeutic Advances in Respiratory Disease 16, pages 175346662110660.
Crossref
Crossref
Chuchu Zhang, Meng Zhang, Yalei Wang, Huaiyu Xiong, Qiangru Huang, Tiankui Shuai & Jian Liu. (2023) Efficacy and Cardiovascular Safety of LAMA in Patients with COPD: A Systematic Review and Meta-Analysis. Journal of Investigative Medicine 69:8, pages 1391-1398.
Crossref
Crossref
M. Zysman, B. Ribeiro Baptista, T. Soumagne, V. Marques da Silva, C. Martin, C. Thibault de Menonville, L. Boyer, B. Degano, C. Morelot Panzini, P.R. Burgel, T. Perez, A. Bourdin, C. Raherison, H. Pégliasco, D. Piperno, C. Zanetti, H. Morel, B. Delclaux, C. Delafosse, A. Lorenzo, B. Housset, F. Chabot, P. Devillier, G. Deslée & N. Roche. (2021) Optimisation du traitement médicamenteux des patients atteints de BPCO en état stable. Position de la Société de pneumologie de langue française. Actualisation 2021. Revue des Maladies Respiratoires 38:5, pages 539-561.
Crossref
Crossref
Yasuhiro Gon, Koichi Nishi, Kazuhiro Sato, Andrea Maes, Shahid Siddiqui, Nobuya Hayashi, Hajime Hirata, Ubaldo J. Martin & Colin Reisner. (2021) Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease. Respiratory Investigation 59:1, pages 135-144.
Crossref
Crossref
Jinping Zheng, Jin-fu Xu, Martin Jenkins, Pryseley Nkouibert Assam, Lijiao Wang & Brian J. Lipworth. (2020) Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials. Respiratory Research 21:1.
Crossref
Crossref
Fernando J. Martinez, Brian J. Lipworth, Klaus F. Rabe, David J. Collier, Gary T. Ferguson, Sanjay Sethi, Gregory J. Feldman, Gerald O’Brien, Martin Jenkins & Colin Reisner. (2020) Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. Respiratory Research 21:1.
Crossref
Crossref
Akira Koarai, Hisatoshi Sugiura, Mitsuhiro Yamada, Tomohiro Ichikawa, Naoya Fujino, Tomotaka Kawayama & Masakazu Ichinose. (2020) Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. BMC Pulmonary Medicine 20:1.
Crossref
Crossref
Antonio Anzueto & Alan Kaplan. (2020) Dual bronchodilators in chronic obstructive pulmonary disease: Evidence from randomized controlled trials and real-world studies. Respiratory Medicine: X 2, pages 100016.
Crossref
Crossref
Ying Huang, Pryseley Nkouibert Assam, Cong Feng, Rong Su, Paul Dorinsky & Michael Gillen. (2020) Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects. Pulmonary Pharmacology & Therapeutics 64, pages 101976.
Crossref
Crossref
Chen Wang, Ting Yang, Jian Kang, Rongchang Chen, Li Zhao, Huijie He, Pryseley N. Assam, Rong Su, Eric Bourne, Shaila Ballal, Kiernan DeAngelis & Paul Dorinsky. (2020) Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS. Advances in Therapy 37:4, pages 1591-1607.
Crossref
Crossref
Wilfried De Backer, Jan De Backer, Ilse Verlinden, Glenn Leemans, Cedric Van Holsbeke, Benjamin Mignot, Martin Jenkins, Dianne Griffis, Stefan Ivanov, Jane Fitzpatrick, Earl St Rose, Ubaldo J. Martin & Colin Reisner. (2020) Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD. Therapeutic Advances in Respiratory Disease 14, pages 175346662091699.
Crossref
Crossref
Edward M. Kerwin, Gary T. Ferguson, Mindy Mo, Kiernan DeAngelis & Paul Dorinsky. (2019) Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. Respiratory Research 20:1.
Crossref
Crossref
Paola Rogliani, Maria Gabriella Matera, Beatrice Ludovica Ritondo, Ilaria De Guido, Ermanno Puxeddu, Mario Cazzola & Luigino Calzetta. (2019) Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. Pulmonary Pharmacology & Therapeutics 59, pages 101841.
Crossref
Crossref
Zaina T. Al-Salama & James E. Frampton. (2019) Glycopyrronium/Formoterol: A Review in COPD. Drugs 79:13, pages 1455-1466.
Crossref
Crossref
François Maltais, Gary T. Ferguson, Gregory J. Feldman, Gaëtan Deslee, Arnaud Bourdin, Harald Fjällbrant, Agnieszka Siwek-Posłuszna, Martin A. Jenkins & Ubaldo J. Martin. (2019) A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD. Advances in Therapy 36:9, pages 2434-2449.
Crossref
Crossref
Qian Chen, Chaoying Hu, Hui Yu, Kai Shen, Pryseley Nkouibert Assam, Michael Gillen, Yun Liu & Paul Dorinsky. (2019) Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. Clinical Therapeutics 41:5, pages 897-909.e1.
Crossref
Crossref
Mohd Kashif Siddiqui, Pragya Shukla, Martin Jenkins, Mario Ouwens, Deniz Guranlioglu, Patrick Darken & Mousumi Biswas. (2019)
Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β
2
-agonist fixed-dose combinations in COPD
. Therapeutic Advances in Respiratory Disease 13, pages 175346661989450.
Crossref
Crossref
Colin Reisner, Joel Miller, Paolo DePetrillo, Andrea Maes, Shahid Siddiqui & Ubaldo J. Martin. (2018) Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects. Pulmonary Pharmacology & Therapeutics 53, pages 33-38.
Crossref
Crossref